M&A / Deals Acquisitive Lilly offers $2.88bn for Merida Bio PharmaphorumLilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.Immunology & InflammationRead full story pharminent August 31, 2026 (Last updated: September 1, 2026) Pharmaphorum Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida. Immunology & Inflammation Read full story Post navigation Previous: FDA Approves Mounjaro Label Expansion to Reduce Cardiovascular Risk in Type 2 DiabetesNext: ESC 2026: Evolocumab explores new frontiers in CV disease prevention Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026